Aurobindo Pharma's subsidiary Eugia Pharma has launched Pomalidomide Capsules (1–4 mg) in the US, targeting a US$3.3 billion market for a third-generation IMiD used in multiple myeloma and Kaposi’s sarcoma.
AI Assistant
Aurobindo Pharma Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.